RenovoRx, Inc. (RNXT) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by RenovoRx, Inc. on July 2, 2026, reporting events occurring on July 1, 2026. The Company is a Delaware corporation with its principal executive offices in Mountain View, California, and its common stock trades on the Nasdaq Capital Market under the symbol "RNXT". The Company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes and Listing Status
- Deficiency Notice: On December 31, 2025, the Company received notice from Nasdaq that its common stock failed to meet the $1.00 minimum bid price requirement (Rule 5550(a)(2)).
- Initial Compliance Period: The Company was initially granted 180 calendar days, ending June 30, 2026, to regain compliance.
- Extension Granted: On July 1, 2026, Nasdaq notified the Company that it is eligible for an additional 180-day compliance period (the "Second Compliance Period"), extending until December 28, 2026.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days during the Second Compliance Period.
Outlook, Risks, and Contingencies
Delisting Risk: If the Company fails to demonstrate compliance with the Minimum Bid Price Requirement by December 28, 2026, Nasdaq will provide written notification that the Common Stock will be delisted.
Appeal Process: In the event of a delisting determination, the Company retains the right to appeal the decision to a Hearings Panel.
Key Facts for Investor Verification
- Verify the current closing bid price of RNXT to assess proximity to the $1.00 threshold.
- Monitor the stock price for 10 consecutive business days to determine if the Company can secure written confirmation of compliance before the December 28, 2026 deadline.
- Review the Company's capitalization strategy or reverse stock split plans, if any, intended to address the bid price deficiency.
- Confirm the status of the Company's emerging growth company designation and any associated reporting exemptions.